CD274 and cancer: According to the expression of PD-L1 in melanoma, NSCLC, and urogenital cancer and the sensitivity of their response to PD-L1 inhibitor, the recurrent ratio of PD-L1 positive and negative cancer is 34.1% and 19.9%, respectively.